Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)

A M Algotar, R Kumar, H M Babiker, S T Dougherty, C H Hsu, H-H Chow, T E Smith, D G Marrero, K S Courneya, I Abraham, J A Ligibel, C A Thomson, A M Algotar, R Kumar, H M Babiker, S T Dougherty, C H Hsu, H-H Chow, T E Smith, D G Marrero, K S Courneya, I Abraham, J A Ligibel, C A Thomson

Abstract

Background: Although androgen deprivation therapy (ADT) for prostate cancer demonstrates improved overall and disease-free survival, it is associated with adverse effects such as obesity and metabolic syndrome that increase risk of cardiometabolic disease and diabetes type 2. ADT also leads to fatigue, depression and erectile dysfunction, which reduce quality of life (QoL). Lifestyle modification has shown promise in reducing obesity, metabolic syndrome and diabetes type 2 in other disease types. However, there is a paucity of data regarding the utility of lifestyle modification in men receiving ADT for prostate cancer.

Methods: The primary aim of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2) is to test the feasibility of conducting a 24-week lifestyle modification intervention in men on ADT for prostate cancer. Additionally, it will also determine the effect of this intervention on weight loss, cardiometabolic markers (secondary aim and markers of interest: serum glucose, insulin resistance, hemoglobin A1C and lipid panel), and QoL (tertiary aim). The intervention will be delivered weekly via telephone for the first 10 weeks and bi-weekly for the remaining 14 weeks. Questionnaires and serum samples will be collected at baseline, week 12, and week 24. Anthropometric measurements will be collected at baseline, week 6, week 12, week 18 and week 24.

Results: We hypothesize that the CLIPP2 intervention will produce a 7% weight loss that will result in improved markers associated with cardiometabolic disease and type 2 diabetes in the study population.

Conclusion: Results will provide insight into the role of lifestyle modification in addressing ADT adverse effects as well as provide preliminary data to inform the development of future lifestyle interventions in this area.

Trial registration: NCT04228055 Clinicaltrials. gov.

Keywords: Androgen Deprivation Therapy; Lifestyle Modification; Prostate Cancer.

© 2021 Published by Elsevier Inc.

Figures

Fig. 1
Fig. 1
Intervention sessions.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA A Cancer J. Clin. 2020;70(1):7–30.
    1. Choi S.M., Kam S.C. Metabolic effects of androgen deprivation therapy. Korean J Urol. 2015;56(1):12–18.
    1. Mitsuzuka K., Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int. J. Urol. 2018;25(1):45–53.
    1. Pinthus J.H. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next? J. Urol. 2015;193(6):1882–1883.
    1. Bosco C., Bosnyak Z., Malmberg A., Adolfsson J., Keating N.L., Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur. Urol. 2015;68(3):386–396.
    1. Epstein M.M., Edgren G., Rider J.R., Mucci L.A., Adami H.O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J. Natl. Cancer Inst. 2012;104(17):1335–1342.
    1. Dieperink K.B., Hansen S., Wagner L., Johansen C., Andersen K.K., Hansen O. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncol. 2012;51(6):722–729.
    1. Duchesne G.M., Woo H.H., King M., Bowe S.J., Stockler M.R., Ames A. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18(9):1192–1201.
    1. Casey R.G., Corcoran N.M., Goldenberg S.L. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J. Androl. 2012;14(2):226–231.
    1. Harrigan M., Cartmel B., Loftfield E., Sanft T., Chagpar A.B., Zhou Y. Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. J. Clin. Oncol. 2016;34(7):669–676.
    1. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346(6):393–403.
    1. Freedland S.J., Howard L., Allen J., Smith J., Stout J., Aronson W. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. Prostate Cancer Prostatic Dis. 2019
    1. Yunfeng G., Weiyang H., Xueyang H., Yilong H., Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: an update meta-analysis. Medicine (Baltim.) 2017;96(27)
    1. Teleni L., Chan R.J., Chan A., Isenring E.A., Vela I., Inder W.J. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr. Relat. Canc. 2016;23(2):101–112.
    1. Penedo F.J., Benedict C., Zhou E.S., Rasheed M., Traeger L., Kava B.R. Association of stress management skills and perceived stress with physical and emotional well-being among advanced prostrate cancer survivors following androgen deprivation treatment. J. Clin. Psychol. Med. Settings. 2013;20(1):25–32.
    1. Hanisch L.J., Gooneratne N.S., Soin K., Gehrman P.R., Vaughn D.J., Coyne J.C. Sleep and daily functioning during androgen deprivation therapy for prostate cancer. Eur. J. Canc. Care. 2011;20(4):549–554.
    1. Algotar A., Hsu C.H., Sherry Chow H.H., Dougherty S., Babiker H.M., Marrero D. Comprehensive lifestyle improvement program for prostate cancer (CLIPP): protocol for a feasibility and exploratory efficacy study in men on androgen deprivation therapy. JMIR Res Protoc. 2019;8(2)
    1. Diabetes Prevention Program Research G., Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–1686.
    1. Sepah S.C., Jiang L., Ellis R.J., McDermott K., Peters A.L. Engagement and outcomes in a digital diabetes prevention program: 3-year update. BMJ Open Diabetes Res Care. 2017;5(1)

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir